A comprehensive analysis of 78 clinical studies reveals striking improvements in cancer treatment efficacy when guided by Molecular Tumor Board recommendations. Among 4,569 patients treated according to MTB protocols, objective response rates improved by 75% compared to those receiving standard care—a substantial margin indicating superior therapeutic outcomes.
This meta-analysis, spanning international research datasets through July 2025, represents the most robust evidence to date for precision medicine’s impact on oncology. Beyond improved response rates, patients experienced a 13% reduction in mortality risk and 27% reduction in disease progression. These quantifiable benefits validate the clinical utility of translating genetic profiling into personalized treatment decisions, offering oncologists and patients alike a data-driven framework for optimizing therapeutic strategies.
Read the full article on GMJ Newsroom.
Was this article helpful?
